Delivery Order SPE2DB24D8001-SPE2DB25FKZKH
Award Date
3/19/25
Potential Completion Date
3/20/25
Potential Value
$9.4K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBPZE, was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $16,771.40 Firm Fixed Price Delivery Order contract is for the provision of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a performance period through November 7, 2023. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the DLA Troop...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKZDM, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a ceiling value of $9,583.28. This contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA, valued at $999,999,999.00. The IDC is part of the DLA...
This federal contract award, identified as SPE2DX15D8002 and SPE2DX24F2TX7, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $13,309.74, is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a completion date of November 29, 2023. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense,...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKZBM, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $11,352.56 firm fixed-price delivery order is for the provision of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA...
This federal contract award, with ID SPE2DB24D8001|SPE2DB24FKYWF, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc. The $9,771.03 firm fixed-price delivery order is for the pharmaceutical product STELARA 90 MG/ML SYRINGEML. Dakota Drug, Inc. is a self-certified small disadvantaged business operating as a for-profit subchapter S corporation that specializes in providing pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of the pharmaceutical product STELARA 90 MG/ML SYRINGE. The contract has a firm fixed price ceiling value of $9,397.47 and a period of performance extending until February 21, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows Dakota Drug, Inc. to provide a...
This federal contract award, with ID SPE2DB24D8001|SPE2DB24FKYYA, is a delivery order valued at $19,198.65 issued by the Defense Logistics Agency (DLA) to the prime contractor, Dakota Drug, Inc. Dakota Drug, Inc. is a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a period of performance through August 20, 2024. This award is not associated with a...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of STELARA 90 MG/ML SYRINGEML. The contract, valued at $8,085.39, has an ultimate completion date of February 18, 2025. This award is part of the DLA Troop Support Medical's ECAT Generation V Program, a larger Indefinite Delivery Contract (IDC) with Dakota Drug, Inc. valued at $999,999,999.00. The IDC allows the company...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $20,476.24 firm fixed-price delivery order is for the pharmaceutical product STELARA 90 MG/ML SYRINGEML, with a period of performance through February 27, 2024. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the procurement of STELARA 90 MG/ML syringes. The contract has a ceiling value of $12,117.01 and a period of performance extending through November 13, 2024. Dakota Drug, Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which enables the company to provide a comprehensive...